Get fast alerts when news breaks on your stocks. Assert your 1-7 days absolutely free demo to StreetInsider Quality right here.
A lot more Effective SofPulse® Results As opposed With Bioelectronics RecoveryRx®
Los Angeles, CA, July 28, 2022 (World NEWSWIRE) — Endonovo Therapeutics Inc. (OTCQB: ENDV) nowadays introduced exceptional comparative results for its SofPulse® clinical device for article-operative soreness aid as opposed with Bioelectronics Corporation’s RecoveryRx®.
The health care remedy comparisons were clinically evaluated centered on 3 scientific trials for RecoveryRx® and 5 published scientific tests for SofPulse®. Product and technical traits comparisons for equally units were bundled in Fda-clearance substance for both company’s Pulsed Electric powered Magnetic Frequency (PEMF) products, which are built to reduce write-up-operative reduction of discomfort and edema (inflammation). Comparison of SofPulse® to RecoveryRx® in technical traits demonstrated superiority of the style, efficacy and overall health added benefits of the Endonovo SofPulse® clinical product.
The RecoveryRx® machine requires 7 days to 14 days to provide professional medical procedure efficacy for publish-operative ache and edema reduction compared with fewer than 18 hours of treatment desired for Endonovo’s SofPulse® to reach healthcare efficacy. In converting comparison results to scientific cure time, RecoveryRx® needs at the very least 84 several hours to 336 several hours of continuous treatment method to realize professional medical efficacy, even though clinical efficacy for Endonovo’s SofPulse® is obtained in 18 several hours of cure.”
Despite the fact that both equally SofPulse® and RecoveryRx® are PEMF devices, there is minor comparison in industry, efficacy or efficiency between the two.
Collier pointed out: “Recover Rx® is a very low-expense, fewer helpful PEMF treatment method possibility to SofPulse®. Both merchandise provide an alternative to possibly addictive opioids for publish-surgical soreness administration. Having said that, facet-by-facet comparisons demonstrate that SofPulse® PEMF layout and technical qualities supply additional effective remedies. SofPulse® is also equipped to deliver professional medical efficacy a great deal quicker and a lot more proficiently then the much less powered confined RecoveryRx® product.”Technical assessment in-depth in the comparison scientific studies indicated:
- Minimal Essential Cure TIME FOR Health care EFFICACY – SofPulse® provides medical efficacy of remedy in two 15-moment treatment plans for a full of 30 minutes of mixed remedy for each day, compared with RecoveryRx®, which involves 12 hours to 24 hours of continual use and remedies for 7 days to14 days to attain medical efficacy.
Summary: SofPulse® obtains professional medical efficacy in much less than the equivalent of one particular day, when compared with RecoveryRx®, requiring 7 times to 14 days to receive a less powerful health-related efficacy for procedure.
- Treatment method Space- Massive COIL System – SofPulse® has 285cm therapy location in contrast with the RecoveryRx® 110cm large coil treatment spot. SofPulse® is developed to produce 2.59X occasions more therapy region then the restricted made RecoveryRx® substantial coil remedy region.
Summary: Only owing to the larger and much more successful design and style of the SofPulse® professional medical product, the place of treatment method is exceptional with SofPulse® when compared with the RecoveryRx® device. These structure variations necessarily mean that SofPulse® can a lot more effectively handle a bigger area of personal injury than the much less helpful RecoveryRx® system.
- DEPTH OF PENETRATION- Big Unit – SofPulse® has a depth of penetration/therapy that is 12.7cm in contrast with RecoveryRx® 7.7cm depth of treatment method for large coil unit. The SofPulse® design provides 1.65X further depth of treatment than the RecoveryRx® significant system style.
- Summary: This depth of penetration/cure is a crucial aspect in getting health care efficacy and more powerful and faster recovery for individuals with put up-operative injuries. Endonovo’s SofPulse® unit design and style outperforms RecoveryRx® machine in offering deeper therapies that assist post-operative wounds get better extra effectively.
- PEAK SPATIAL Energy – SofPulse device has far more than 10,000 situations much more peak spatial electrical power than RecoveryRx® equipment. SofPulse® is intended with significantly better spatial electricity and due to the fact of this difference is able to deliver its patented PEMF therapeutic frequency and provide health-related efficacy effects in twelve 15-minute remedies day-to-day for 8 days compared with the RecoveryRx® demanded therapy occasions to accomplish health care efficacy of 12 several hours to 24 hours each day with demanded ongoing utilization more than 7 times to 14 times.
Summary: SofPulse® has outstanding electricity and obtains professional medical efficacy speedier and so can address patient’s post-operative pain and edema much more proficiently than the significantly significantly less powerful, very confined RecoveryRx® system.
- Energy For each PULSE – SofPulse® applies 571 a lot more vitality for each pulse than RecoveryRx® OR 4mW for SofPulse® in contrast with .007mW for RecoveryRx®.
- Summary: The energy per pulse is a important issue in decreasing restoration instances and increasing clinical efficacy of the PEMF treatment for article-operative patients in reduction of pain and edema. The considerable electricity big difference of SofPulse® outperforms RecoveryRx® is this category.
For comprehensive references with regards to promises in this information release, make contact with Endonovo’s Trader Relations.
About Endonovo Therapeutics, Inc.
Endonovo Therapeutics is a professional-phase developer of noninvasive wearable Electroceuticals® therapeutic devices for ache reduction, general wellness and wound curatives. The Firm’s present-day portfolio of business and medical-stage wearable Electroceuticals® therapeutic gadgets addresses wound therapeutic, ache, publish-surgical pain and edema, cardiovascular ailment, persistent kidney condition, and central anxious process (CNS) diseases, like traumatic brain damage (TBI), acute concussions, write-up-concussion syndrome and various sclerosis. The Firm’s noninvasive Electroceutical® therapeutic gadget, SofPulse®, which works by using pulsed quick-wave radiofrequency at 27.12 MHz, has been Fda-cleared and CE marked for the palliative treatment of comfortable tissue accidents and put up-operative ache and edema. It also has CMS countrywide protection for the therapy of chronic wounds. The Firm’s recent portfolio of preclinical-phase Electroceuticals® therapeutic products addresses persistent kidney sickness, liver illness, non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disorder (PAD), and ischemic stroke. The Company’s noninvasive, wearable Electroceuticals® therapeutic gadgets do the job by restoring vital electrochemical procedures that initiate anti-inflammatory and development factor cascades required for healing to come about.
Protected Harbor Assertion
This push release contains information and facts that constitutes ahead-looking statements made pursuant to the secure harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, developments, evaluation, and other data contained in this push release like terms this sort of as “anticipate,” “imagine,” “approach,” “estimate,” “anticipate,” “intend,” and other comparable expressions of view, represent ahead-searching statements. Any this sort of forward-wanting statements contain risks and uncertainties that could lead to precise success to differ materially from any long term outcomes explained inside of the forward-seeking statements. Danger aspects that could add to such discrepancies involve all those issues more thoroughly disclosed in the Company’s studies submitted with the Securities and Trade Fee. The ahead-hunting info provided herein represents the Company’s estimates as of the date of the press release, and subsequent occasions and developments might induce the Firm’s estimates to modify. The Enterprise specifically disclaims any obligation to update the forward-seeking information and facts in the upcoming. Therefore, this forward-searching details should really not be relied upon as representing the Firm’s estimates of its long term fiscal functionality as of any date subsequent to the date of this press release.
Investor Relations Get hold of:Endonovo Therapeutics, Inc.Mr. Steve Barnes(800) 701-1223 Ext. 108[email protected] www.endonovo.com
Media Get hold of:Gregory A. McAndrewsGreg McAndrews & Associates(310) 804-7037[email protected]
Source: Endonovo Therapeutics, Inc.